{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:45:36Z","timestamp":1789245936574,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jtocrr.2023.100622","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T19:25:45Z","timestamp":1702927545000},"page":"100622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC"],"prefix":"10.1016","volume":"5","author":[{"given":"Vanita","family":"Noronha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4214-5799","authenticated-orcid":false,"given":"Nandini S.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Maruti","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Chandrakanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sucheta","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Dhanawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oindrila Roy","family":"Chowdhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaykumar Chandrabhan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Goud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srushti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Karuvandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal Naishadh","family":"Jobanputra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshit Kalpeshkumar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minit Jalan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupjyoti","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhwaniben","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritam","family":"Joarder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupa","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaspreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilendu","family":"Purandare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Janu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2023.100622_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4103\/crst.crst_61_21","volume":"4","author":"Prabhash","year":"2021","journal-title":"Cancer Res Stat Treat"},{"key":"10.1016\/j.jtocrr.2023.100622_bib2","first-page":"649","article-title":"The need for third-line treatment in non-small cell lung cancer: an overview of new options","volume":"31","author":"Syrigos","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtocrr.2023.100622_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtocrr.2023.100622_bib4","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1200\/JCO.22.02499","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer","volume":"41","author":"Fukuoka","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100622_bib5","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jtocrr.2023.100622_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.cad.0000203381.99490.ab","article-title":"Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer","volume":"17","author":"Cufer","year":"2006","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.jtocrr.2023.100622_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2023.100622_bib8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/EDBK_351021","article-title":"Barriers to access: global variability in implementing treatment advances in lung cancer","author":"Febbraro","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtocrr.2023.100622_bib9","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3332\/ecancer.2022.1464","article-title":"Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India","volume":"16","author":"Patil","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.jtocrr.2023.100622_bib10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/EDBK_100028","article-title":"An arm and a leg: the rising cost of cancer drugs and impact on access","author":"Leighl","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtocrr.2023.100622_bib12","author":"Pal"},{"issue":"suppl 14","key":"10.1016\/j.jtocrr.2023.100622_bib13","article-title":"Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: an exploratory analysis","volume":"22","author":"Pujol","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2023.100622_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejcsup.2014.03.003","article-title":"Monitoring and optimising cognitive function in cancer patients: present knowledge and future directions","volume":"12","author":"Schagen","year":"2014","journal-title":"EJC Suppl"},{"key":"10.1016\/j.jtocrr.2023.100622_bib15","doi-asserted-by":"crossref","first-page":"578","DOI":"10.18632\/oncotarget.27905","article-title":"Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations","volume":"12","author":"Joshi","year":"2021","journal-title":"Oncotarget"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323001650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364323001650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:39:02Z","timestamp":1762987142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364323001650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2666364323001650"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100622","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100622"}}